Shigehisa Kitano

32PUBLICATIONS
185CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsMolecular targetsPredictive and prognostic markersTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|May 26, 2026
Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in patients with locally advanced NSCLC.

|Mar 15, 2026
Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer.

Takeru Wakatsuki, Noriko Yamamoto, Naoki Ishizuka

|Mar 04, 2026
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or <i>HER2</i>-mutant solid tumors.

Alison M Schram, John J Park, Antoine Italiano

|Jan 27, 2026
Immunological profile of the tumor immune microenvironment of upper tract urothelial carcinoma predicts recurrence patterns.

Kenta Takahashi, Daiki Ikarashi, Shigehisa Kitano

|Jan 27, 2026
Non-Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors.

Hiroki Ishihara, Yu-Yu Liu, Riu Yamashita

|Aug 22, 2025
Clinical potential of antibody-drug conjugates in early-phase clinical trials for late-line treatment of advanced solid tumors.

Ippei Miyamoto, Takahiro Kogawa, Kana Kurokawa

Pageof 6

Frequent Collaborators

5 joint publications

Noboru Yamamoto

4 joint publications

Kazunori Aoki

4 joint publications

Nobuyoshi Hiraoka

3 joint publications

Tatsuhiro Shibata